Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.42 |
| ▸ | GRM5 | P41594 | 5/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.42 |
| ▸ | GRM6 | O15303 | 10/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 7/20 | 0.40 |
| ▸ | GRM8 | O00222 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12800122 | 1.00 | GRM2 (0.42) | GRM2GRM5GRM1GRM6GRM3 | |
| SCHEMBL3586760 | 0.77 | GRM2 (0.47) | GRM2GRM5GRM1GRM6GRM3 | |
| Hydrochloric Acid SCHEMBL32674380 | 0.74 | — | — | |
| SCHEMBL32674009 | 0.72 | GAA (0.34) | — | |
| SCHEMBL25331423 | 0.68 | APLNR (0.34) | — | |
| SCHEMBL24868026 | 0.68 | APLNR (0.34) | — | |
| SCHEMBL25330072 | 0.68 | APLNR (0.34) | — | |
| SCHEMBL8521812 | 0.67 | — | — | |
| SCHEMBL20524196 | 0.65 | — | — | |
| SCHEMBL15428478 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | GRM2 1175/4885GRM5 1083/4885GRM1 1079/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | GRM2 1175/4885GRM5 1083/4885GRM1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.